Roxatidine acetate: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'KEGG'). |
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_Pharmacology|errors |
||
| Line 2: | Line 2: | ||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = IV9VHT3YUM |
| UNII = IV9VHT3YUM |
||
| verifiedrevid = |
| verifiedrevid = 443579961 |
||
|<!--All drugbox data refers to roxatidine acetate--> |
|<!--All drugbox data refers to roxatidine acetate--> |
||
|IUPAC_name = 2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate |
|IUPAC_name = 2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate |
||
| Line 22: | Line 22: | ||
| ATC_suffix=BA06 |
| ATC_suffix=BA06 |
||
| ATC_supplemental= |
| ATC_supplemental= |
||
| KEGG_Ref = {{keggcite|correct|kegg}} |
|||
| KEGG = D08495 |
| KEGG = D08495 |
||
| PubChem=5105 |
| PubChem=5105 |
||
Revision as of 22:48, 7 August 2011
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 80–90% |
| Protein binding | 5–7% |
| Metabolism | Hepatic deacetylation Minor involvement of CYP2D6 and CYP2A6 |
| Elimination half-life | 5–7 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H28N2O4 |
| Molar mass | 348.437 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Roxatidine acetate is a specific and competitive H2 receptor antagonist. The antisecretory effect of roxatidine acetate is mediated by its main metabolite, roxatidine. Pharmacodynamic studies revealed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[citation needed]
Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver. [citation needed]
It is currently sold in South Africa under the tradename Roxit.
 |
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |